Sinovac benefits from Chinese vaccine order
This article was originally published in Scrip
Executive Summary
Sinovac Biotech has received a Yuan87 million ($12.8 million) order from China's ministry of public health for its hepatitis A vaccine Healive. Sinovac will be the sole supplier of the inactivated vaccine under a tender for a national inoculation campaign. This will cover children aged 18 months to 12 years in 32 cities and counties across nine provinces, the Beijing-based company said. Sinovac recently increased its annual production capacity for Healive to 20 million doses, and is also targeting the private market. It also markets other hepatitis and flu vaccines and is working on pandemic flu and Japanese encephalitis vaccines.